William Denney, MD
Internal Medicine · Richmond, VANPI 1366888505
Payments from drug & device makers
Across 545 payments — averaging $19.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- AstraZeneca$1K
- Actelion Pharmaceuticals US, Inc.$956
- Boehringer Ingelheim$636
- Intuitive Surgical$539
- Mallinckrodt Hospital Products Inc.$425
- plus $4K from 32 others
What the payments were for
- Travel & lodging$4174%
- Food & beverage$10,35096%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 181 | $3,203 |
| AstraZeneca | 53 | $1,185 |
| Actelion Pharmaceuticals US, Inc. | 41 | $956 |
| Boehringer Ingelheim | 37 | $636 |
| Intuitive Surgical | 6 | $539 |
| Mallinckrodt Hospital Products Inc. | 20 | $425 |
| Sanofi | 17 | $416 |
| United Therapeutics Corporation | 20 | $368 |
| Mylan Specialty L.p. | 16 | $286 |
| Jazz Pharmaceuticals Inc. | 11 | $247 |
| Regeneron Healthcare Solutions, Inc. | 9 | $240 |
| Bayer | 13 | $236 |
| Johnson & Johnson | 16 | $234 |
| Merck | 12 | $224 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $180 |
| Genentech USA, Inc. | 5 | $172 |
| Verona Pharma, Inc. | 14 | $160 |
| Astellas Pharma US Inc | 7 | $137 |
| Pfizer | 7 | $128 |
| Insmed, Inc. | 6 | $110 |
| E.r. Squibb & Sons, L.L.C. | 7 | $98 |
| Mallinckrodt Enterprises LLC | 4 | $90 |
| Viatris Specialty LLC | 4 | $78 |
| Electromed, Inc. | 8 | $62 |
| ANI Pharmaceuticals, Inc. | 2 | $47 |
| Advanced Respiratory, Inc | 2 | $40 |
| Amgen | 2 | $38 |
| Liquidia Technologies, Inc. | 2 | $36 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $30 |
| Novartis | 2 | $29 |
| Vapotherm Inc | 2 | $24 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Baxter Healthcare | 1 | $18 |
| Portola Pharmaceuticals, LLC | 1 | $18 |
| Pulmonx Corporation | 1 | $17 |
| Gilead | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| La Jolla Pharmaceutical Company | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$398
- DUPIXENT$209
- TRELEGY ELLIPTA$125
- NUCALA$125
- UPTRAVI$112
- OPSUMIT$112
- BREZTRI$102
- AIRSUPRA$102
- FASENRA$102
How this compares
$10,767 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fasenra PenBenralizumab | 39 | $221,835 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 231 | $167,823 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 101 | $68,068 |
| Spiriva RespimatTiotropium Bromide | 99 | $61,356 |
| EliquisApixaban | 50 | $37,737 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 47 | $32,477 |
| XareltoRivaroxaban | 36 | $28,729 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $15,150 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 35 | $13,785 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $13,655 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 406 | $11,753 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $11,088 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 41 | $7,541 |
| BreynaBudesonide/Formoterol Fumarate | 34 | $4,894 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $3,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $3,203 | $195,283292 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,185 | $97,003200 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $636 | $93,833146 claims |
| PfizerEliquis | $128 | $37,73750 claims |
| Johnson & JohnsonXarelto | $234 | $28,72936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Richmond
- Leroy VaughanRichmond$20.8M
- Andrew PoklepovicRichmond$4.6M
- Richard JacksonRichmond$2.5M
- Lawrence SchwartzRichmond$2.4M
- John HoekstraRichmond$344K
- Franklin ZieveRichmond$337K
- Wally SmithRichmond$333K
- Thokozeni LipatoRichmond$247K
- John BarrettRichmond$217K
- Alan DowRichmond$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.